<DOC>
	<DOCNO>NCT00585221</DOCNO>
	<brief_summary>Imatinib ( IM ) dramatically improve survival gastrointestinal stromal tumor ( GIST ) . However , patient become resistant IM less two year . This clinical trial combine target therapy ( IM ) immunotherapy ( peginterferon α-2b ) . Hypothesis : Apoptosis/necrosis imatinib-sensitive GIST release GIST-specific antigen vivo Peginterferon α-2b fulfills role cytokine signal ( danger signal ) , combination induce effective innate adaptive anti-GIST immunity , eradicate imatinib-resistant clone GIST stem cell via recognition common antigen share imatinib-sensitive GIST , lead improve response rate remission duration .</brief_summary>
	<brief_title>Study Imatinib Peginterferon α-2b Gastrointestinal Stromal Tumor ( GIST ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients must &gt; 18 year old . 2 . Patients must histologic evidence GIST ( Gastrointestinal Stromal Tumors ) . 3 . If genotyping do , paraffin block 7 unstained slide biopsy unstained slide require genotyping within one week enrollment . 4 . Stage I , II , III patient eligible primary tumor 6 centimeter large . All stage IV ( 4 ) metastatic recurrent GIST patient imatinibnaïve eligible . For stage IV patient initial good response imatinib stop imatinib 10 month longer . GIST patient receive imatinib `` adjuvant '' treatment past , later develop recurrence eligible DFS &gt; 6 month completion adjuvant imatinib . 5 . Patients must Zubrod Performance Status 01 Karnofsky Performance Status &gt; 70 % . 6 . Patients must life expectancy twelve month . 7 . Patients must negative serology test HIV ( Human immunodeficiency virus ) . Hepatitis B , Hepatitis C , ANA ( antinuclear antibody ) titer within 2 time upper limit normal within 28 day enrollment . Patients must clinical rheumatoid arthritis ( RA ) . RA criterion follow : 1 ) morning stiffness around joint last least 1 hour maximal improvement ; 2 ) soft tissue swell ( arthritis ) 3 joint area observe physician ; 3 ) swelling ( arthritis ) proximal interphalangeal , metacarpophalangeal , wrist joint ; 4 ) symmetric swell ( arthritis ) ; 5 ) rheumatoid nodule ; 6 ) presence rheumatoid factor ; 7 ) radiographic erosion and/or periarticular osteopenia hand and/or wrist joint . Criteria 1 4 must present least 6 week . RA define presence 4 criterion . Patients must normal thyroid function test ( 1.5 time upper low normal limit ) include TSH ( Thyroidstimulating Hormone ) , T4 ( Thyroxine ) within 4 week enrollment . 8 . Patients must adequate liver function evidence follow : total bilirubin , AST ( aspartate aminotransferase ) &lt; 2 time institutional upper limit normal assess within 2 week enrollment . If patient extensive liver metastasis main cause abnormal liver function , requirement apply . The Principal Investigator use clinical judgment . 9 . Patients must serum creatinine &lt; 2 miligrams/deciliter within 2 week enrollment . 10 . Patients must WBC ( white blood cell ) &gt; 3x109 /L , absolute neutrophil count ( ANC ) &gt; 1.5 x 109 /L platelet count &gt; 125 x 109 /L , hemoglobin &gt; 11 within 2 week enrollment . 11 . Patients must PT ( prothrombin time ) , PTT ( partial thromboplastin time ) INR ( international normalize ratio ) &lt; institutional upper limit normal within 4 week enrollment . 12 . Patients must history malignancy atypical melanocytic hyperplasia , basal squamous skin cancer situ cancer , lobular carcinoma breast situ , cervical cancer situ , Clark I melanoma situ continuously disease free 5 year prior enrollment . 13 . Patients may receive chemotherapy within 30 day prior enrollment . 14 . Patients must negative serum pregnancy test female childbearing potential . 15 . Patients must agree use accepted effective method contraception Pegintron period 18 month complete discontinue Pegintron . 16 . Patients may autoimmune disorder , immunodeficiency . 17 . Patients may undergo splenectomy gastrectomy reason . Total gastrectomy usually result poor tolerance recommend dose Imatinib . 18 . Patients require antihistamine , nonsteroidal antiinflammatory drug , corticosteroid . 19 . Patients may active ischemic heart disease cerebrovascular disease , congestive heart failure ( New York Heart Association class III IV ) , angina require ongoing medication . EKG ( Electrocardiography ) may show acute ischemic change acute heart rhythm change . 20 . Patients show history Central Nervous System demyelination , inflammatory disease hereditary acquire peripheral neuropathy great Grade 2 . 21 . Patients ongoing psychiatric disorder , surgical condition , medical condition require treatment regimen may interfere completion trial evaluation safety efficacy study compound . For question , please contact study Principal Investigator . 22 . Patients take coumadin , lovenox heparin metallic heart valve hypercoagulability . 23 . Patients must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . 24 . In opinion Principal Investigator patient eligible good candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gastrointestinal stromal tumor</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Peginterferon α-2b</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Targeted therapy</keyword>
</DOC>